Interim report January – September 2017
CEO’s comments EQL Pharma continues to show weak numbers in parity with our previously announced financial outlook. The temporary withdrawal of Hydroxyzine EQL Pharma continues to effect sales and earnings. During the quarter, the drug Zonisamid EQL Pharma has been launched on the Danish market, while at the same time the drug Eletriptan EQL Pharma has been approved within the framework of a DCP. We continue to develop our portfolio and in total our pipeline has been expanded with three products, both in licensed products and developmental products are represented in the expansion.